A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis
Status: Recruiting
Location: See all (25) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Chronic AD that has been present for ≥6 months
• Validated-Investigator's Global Assessment score of ≥3
• EASI of ≥16
• BSA of AD involvement of ≥10%
Locations
United States
California
Center for Dermatology Clinical Research
RECRUITING
Fremont
Metropolis Dermatology - Downtown Los Angeles
RECRUITING
Los Angeles
Skin and Beauty Center
RECRUITING
Pasadena
Florida
Skin Care Research, LLC
RECRUITING
Boca Raton
Driven Research, LLC
RECRUITING
Coral Gables
Skin Care Research - Hollywood Dermatology
RECRUITING
Hollywood
TrueBlue Clinical Research
RECRUITING
Tampa
Indiana
DS Research
RECRUITING
Clarksville
Kentucky
Equity Medical
RECRUITING
Bowling Green
Maryland
Aesthetic and Dermatology Center
RECRUITING
Rockville
Michigan
Great Lakes Research Group, Inc.
RECRUITING
Bay City
Revival Research Institute, LLC
RECRUITING
Troy
North Carolina
Wilmington Dermatology Center
RECRUITING
Wilmington
New York
Empire Dermatology
RECRUITING
East Syracuse
Equity Medical
RECRUITING
New York
Skin Search of Rochester, Inc.
RECRUITING
Rochester
Tennessee
International Clinical Research - Murfreesboro
RECRUITING
Murfreesboro
Texas
Stryde Research
RECRUITING
Lewisville
Progressive Clinical Research
RECRUITING
San Antonio
Utah
Jordan Valley Dermatology Center
RECRUITING
South Jordan
Other Locations
New Zealand
Optimal Clinical Trials
RECRUITING
Auckland
Optimal Clinical Trials
RECRUITING
Auckland
Pacific Clinical Research Network (PCRN) - Christchurch
RECRUITING
Christchurch Central City
Clinical Trials NZ Limited
RECRUITING
Hamilton
Momentum Clinical Research Lower Hutt
RECRUITING
Lower Hutt
Contact Information
Primary
Jill Abbey, MBA
jill.abbey@evommune.com
925-286-0832
Time Frame
Start Date: 2025-08-26
Estimated Completion Date: 2026-07
Participants
Target number of participants: 120
Treatments
Experimental: Dose 1
Orally administered EVO756, Dose 1
Experimental: Dose 2
Orally administered EVO756, Dose 2
Experimental: Dose 3
Orally administered EVO756, Dose 3
Placebo_comparator: Placebo
Placebo control
Related Therapeutic Areas
Sponsors
Leads: Evommune, Inc.